OSE Immunotherapeutics SA (EPA:OSE)
France · Delayed Price · Currency is EUR 4.300
-0.088 (-2.01%)
At close: Feb 20, 2026
OSE Immunotherapeutics Employees
OSE Immunotherapeutics had 64 employees as of December 31, 2024. The number of employees increased by 9 or 16.36% compared to the previous year.
Employees
64
Change (1Y)
9
Growth (1Y)
16.36%
Revenue / Employee
€27,844
Profits / Employee
€508,109
Market Cap
96.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 64 | 9 | 16.36% |
| Dec 31, 2023 | 55 | -12 | -17.91% |
| Dec 31, 2022 | 67 | 6 | 9.84% |
| Dec 31, 2021 | 61 | 10 | 19.61% |
| Dec 31, 2020 | 51 | 9 | 21.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Innate Pharma | 174 |
| Transgene | 147 |
| Adocia | 77 |
| Sensorion | 68 |
| MaaT Pharma | 65 |
| Fermentalg | 63 |
| ABIONYX Pharma | 51 |
OSE Immunotherapeutics News
- 24 days ago - OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab - GlobeNewsWire
- 4 weeks ago - OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) - GlobeNewsWire
- 2 months ago - OSE Immunotherapeutics SA (ORPOF) Discusses Strategic Plan With Four Opportunities for Value Creation Transcript - Seeking Alpha
- 2 months ago - OSE Immunotherapeutics Unveils 2026-2028 Strategic Plan With Four Value-Creating Opportunities - Nasdaq
- 2 months ago - OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development - Benzinga
- 5 months ago - OSE Immunotherapeutics (ORPOF) Appoints Interim CEO Marc Le Bozec - GuruFocus
- 5 months ago - OSE Immunotherapeutics replaces CEO Nicolas Poirier, appoints Marc Le Bozec as interim CEO - Seeking Alpha
- 5 months ago - OSE Immunotherapeutics SA (ORPOF) Shareholder/Analyst Call Transcript - Seeking Alpha